NATCO Pharma launches generic blood cancer treatment medicine in US
- IBEF
- March 5, 2026
Indian pharmaceutical firm NATCO Pharma has launched generic Pomalidomide capsules for the treatment of blood and bone marrow cancers, including multiple myeloma and Kaposi sarcoma, in the United States in collaboration with Breckenridge Pharmaceutical, Incorporated. The generic version of Celgene’s Pomalyst is available in 1mg, 2mg, 3mg, and 4mg strengths and will be distributed mainly through specialty pharmacies and clinics across the US. According to industry estimates, Pomalidomide capsules had annual sales of about Rs. 29,491 crore (US$ 3.2 billion) in the US for the 12 months ended September 2025, reflecting the high demand for this oncology therapy. NATCO believes it has 180 days of shared exclusivity for marketing the product based on information provided by the US Food and Drug Administration (FDA), offering a significant opportunity to strengthen its presence in the specialty and complex generics segment.
NATCO Pharma’s Vice Chairman and CEO, Mr. Rajeev Nannapaneni, said the launch further enhances the company’s oncology and specialty portfolio in the US and highlights its mission of making specialty medicines accessible to patients worldwide. Breckenridge’s leadership also emphasized the importance of high-quality, affordable generics and noted patient cost-sharing assistance programs to help eligible patients reduce treatment delays and maintain continuity of care. The product’s approval and launch underscore NATCO’s ongoing commitment to bringing complex and specialty treatments to global markets, particularly in therapeutic areas where access and affordability remain critical challenges for patients.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
